Archive for the ‘Cardium Therapeutics Inc. CXM’ Category

Cardium Therapeutics, Inc. (CXM) Enters Distribution Agreement Targeting Governmental Medical Facilities

Thursday, August 1st, 2013

Today before the open, Cardium Therapeutics announced that it has signed a distribution agreement with AvKARE encompassing government medical facilities throughout the United States. The new commercialization arrangement with AvKARE effectively replaces an earlier arrangement with Academy Medical.

Cardium chose to transfer the Excellagen distribution responsibilities to AvKARE, a licensed manufacturer/wholesaler of pharmaceuticals, disposable medical supplies, and capital medical equipment. The officers and management team at AvKARE have more than 80 years’ experience in the pharmaceutical and medical supply industry.

As part of the agreement, AvKARE provides five direct wound care experts and allows Cardium’s 25 distributor representatives access to all government accounts. The company serves the Department of Defense, Veterans Hospitals, NASA, TriCare, Dept. of Agriculture, Indian Health Services, USDA, U.S. Army, Air Force, Navy, and USMC, as well as Group Purchasing Organizations that include Amerinet, Innovatix, Health Trust Purchasing Group, IPC, Broadlane/MedAssets and Premier.

To learn more about AvKARE, visit www.Excellagen.com/AvKARE

To learn more about Cardium, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Raises $4.0M in Preferred Stock Financing

Friday, July 19th, 2013

Cardium Therapeutics has completed the second tranche of its previously announced registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the total gross proceeds of the offering to approximately $4.0 million.

For a detailed description of the terms of the securities purchase agreement as well as the rights, privileges, and preferences of the Series A Convertible Preferred Stock, view CXM’s current report on Form 8-K here: http://dtg.fm/45Ml.

CXM is an asset-based health sciences and regenerative medicine company engaged in the acquisition and strategic development of products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization.

For more information, visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Channels Resources to Fulfill Strategic Business, Growth Strategy

Tuesday, July 16th, 2013

Cardium Therapeutics focuses on the fields of health sciences and regenerative medicine to carry out its business model of acquiring and developing new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. Prospective acquisition targets are selected based on their potential pathways to commercialization, partnering, and other economic monetizations.

The company’s medical opportunities portfolio is currently comprised of the Tissue Repair Company, Cardium Biologics, and the newly acquired To Go Brands healthy nutraceutical supplement business. Cardium’s lead commercial product, Excellagen® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Lead clinical development product candidate Generx® is a DNA-based angiogenic biologic for the treatment of patients with myocardial ischemia due to coronary artery disease.

The overarching strategy is to create multiple opportunities for success without relying on any single technology platform or product type, building on core products and product candidates to develop a portfolio of medical product candidates at various stages of development and to commercialize these products in a timely and effective manner.

Cardium’s business strategy at this time primarily seeks to:

• Advance forward the ASPIRE Generx® Clinical Study for patients with advanced coronary artery disease at major medical centers in Russia in connection with commercialization plans covering the marketing and sale of Generx in the Russian Federation (and CIS);

• Seek clinical development and commercialization partners for Generx® as a cost-effective front-line therapy in other newly industrializing countries, such as India, China, and Brazil, for patients who may not have access to advanced surgical therapies, such as angioplasty/stents and coronary artery by-pass surgery;

• Secure commercialization partners for marketing and sales of Excellagen® in the U.S., as well as internationally, and develop additional tissue regeneration product extensions to include small molecule drugs, peptides, stem cells, conditioned cell media, DNA-based biologic products, and Excellagen-based antimicrobials;

• Broaden and grow the Go Brands® healthy nutraceutical supplement brand platform;

• Continue to review acquisitions of other companies and businesses, as well as licenses covering product opportunities and technologies on favorable economic terms consistent with Cardium’s long-term business strategy.

For more information, visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Positions Itself for Near-Term and Long-Term Growth

Tuesday, July 9th, 2013

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, is remarkably well balanced for ongoing growth in the health and therapeutic marketplace. The company has products that cover the range from well-established revenue generators, to relatively recently introduced products just starting to expand commercially, to products still under development.

Cardium subsidiary, To Go Brands, has a wide portfolio of healthy-lifestyle products, already proven in the marketplace and generating dependable revenue. The company sells 100% natural nutraceutical powder mixes, supplements, and chews, all designed for convenient use by health-conscious consumers with an active lifestyle. Although the brands are well established, their presence continues to grow, with new products being developed.

A more recently introduced product, rapidly expanding its market signature, is Cardium’s Excellagen, a pharmaceutically-formulated gel that has been shown to promote healing of all types of wounds. Excellagen is for use by doctors, and has been FDA-cleared to treat neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds. The company recently announced a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration healthcare system and military hospitals, a huge market.

Cardium’s longer term product candidate is Generx, a unique DNA-based angiogenic growth factor therapeutic, designed to actually stimulate the growth of blood vessels in the heart, for patients with insufficient blood flow due to heart disease. Unlike traditional drug therapies for heart disease, which are focused simply on reducing pain, Generx is designed to actually encourage the growth of blood vessels. In parts of the world where costly and elaborate heart surgeries are not as readily available, Generx is an important potential new option for the treatment of heart disease. Still under trial, Generx represents the company’s major link to future revenue growth.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Tackles Three Major Markets at Once

Monday, July 1st, 2013

Ask any physician or health care professional what America’s biggest single health problem is and you will likely get an answer that points to cardiovascular disease and the lifestyle issues that promote it, such as obesity. Heart disease has long been the number one killer in the U.S., and various lifestyle factors have increasingly been implicated as a principal cause. Specifically, poor eating habits and a sedentary lifestyle have been shown to encourage obesity and type 2 diabetes. Type 2 diabetes, in turn, can lead to a number of serious problems, one of which is cardiovascular disease.

The link between lifestyle, diabetes, and cardiovascular disease is a major focus because of the numbers involved. The U.S. now has the highest rate of obesity in the world, with roughly 30% of all Americans listed as obese. The growth in obesity has helped fuel an alarming growth rate in diabetes, with some states experiencing a doubling of the diabetes rate in just 5 years. Diabetes is now known to feed heart disease, and approximately 600,000 people die annually in the U.S. from heart disease. Such numbers have generated a vast and growing market for health products and drugs that can address this chain of disease which threatens to cripple entire generations and dramatically affect the nation’s economy.

California-based Cardium Therapeutics, a health sciences and regenerative medicine company, is unique in that its products directly address all three of these major markets.

• Cardium’s lifestyle subsidiary, To Go Brands, produces all-natural health supplements that are designed for easy and convenient use, helping people to get the nutrition they need while losing weight.
• Cardium’s Excellagen is an FDA-approved easy-to-use gel that has been shown to speed and improve the healing process for wounds, including their primary target market of foot wounds caused by diabetes.
• Cardium’s Generx is the first-of-its-kind drug that actually promotes the growth of blood vessels around the heart, enhancing blood flow for heart disease patients, unlike other heart drugs that simply address the pain.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Positioned to Advance Leading Products with Experienced Leadership at the Helm

Tuesday, June 25th, 2013

Cardium Therapeutics has established a diversified portfolio of medical products with large market potential. Armed with a capital-efficient, asset-based business strategy, the company is positioned to continue to build its portfolio with balanced risk/return opportunities in a variety of markets and is working to secure approval for marketing and sale in South Korea and the European Union.

Company CEO Christopher J. Reinhard founded the company in December 2003, backed by nearly 15 years of focus on the commercial development of cardiovascular growth factor therapeutics.

Under Reinhard’s leadership, Cardium is working to advance its ASPIRE Generx® clinical study at major medical centers in Russia. The company is also seeking clinical development and commercialization partners for Generx® in countries such as India, China and Brazil.

The Generx® product candidate is a minimally invasive DNA-based angiogenic growth factor therapy in development for the treatment of patients with advanced coronary artery disease. The product is being developed for international markets as an alternative treatment for patients who may not have access to surgical revascularization procedures such as coronary artery bypass surgery and angioplasty/stents.

Cardium’s Excellagen® is a syringe-based collagen gel designed to speed the growth of granulation tissue and to trigger the wound healing process. The product is FDA-cleared as treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds. Cardium is seeking commercialization partners for the marketing and sale of the product both domestically and internationally.

Cardium’s To Go Brands® develops, markets, and sells more than 25 products in support of a healthy lifestyle. The product line includes nutraceutical powder mixes, supplements, and chews sold through mass, food, and drug retailers.

Cardium is working to broaden and grow its To Go Brands® nutraceutical supplement brand platform and continues to review acquisitions of other companies and businesses to identify additional product opportunities and technologies.

For more information, visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Builds Diverse Portfolio with Broad Commercialization Opportunities

Tuesday, June 18th, 2013

It’s not something you’d expect to find in a regenerative medicine company’s portfolio, but Cardium Therapeutics’ To Go Brands healthy nutraceutical supplement business is complementary to the company’s overarching mission of meeting unmet medical needs as part of an individual’s overall health and wellness.

Cardium in October 2012 acquired the assets, business, and product portfolio of To Go Brands, which develops and markets more than 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles.

The brand’s Healthy To Go product line offers a host of healthy product offerings distributed through mass food and drug channels at retailers such as Whole Foods, CVS, Kroger, GNC, Vitamin Shoppe, and more.

Within Cardium’s medical opportunities portfolio is its lead commercial product, Excellagen®, topical gel for wound care management. Excellagen is FDA-approved for the marketing and sale in the United States. In addition to its plans to advance Excellagen’s commercial reach in the U.S. and internationally, Cardium plans to develop new extensions for additional wound care applications, and its working to achieve regulatory approval for the marketing and sale of the product in South Korea and the European Union.

The company’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its phase 3 registration study for Generx in Russia.

For more information, visit www.cardiumthx.com or www.togobrands.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Addresses Two Major Diseases of the Digital Age

Tuesday, June 11th, 2013

When we contemplate the effects that digital electronics has had on health, we are likely to think of the truly amazing progress made in things like medical diagnostics or medical information processing and communication. What is becoming increasingly clear, however, are the negative effects that our move to a digital world has produced. Although research in this area is still limited and ongoing, there now seems to be little doubt that the sedentary lifestyle encouraged by the growing, almost addictive use of computers and mobile devices is seriously threatening our nation’s and ultimately the world’s health. Two of the most significant areas of concern are diabetes and heart disease.

Even a cursory look at statistics for diagnosed diabetes in the U.S. reveals a sharp rise in cases, beginning around 1990 when personal computers and the Web first began working their way into modern daily life. Within two decades, the number of diabetes cases in the U.S. had tripled. Obesity has been related directly to lack of activity in conjunction with sugary foods, and this condition has risen dramatically, more than doubling in children. Obesity is seen as a leading contributor for both diabetes and heart disease. Although new high-tech treatments have been able to help stem deaths from heart disease, it is still a growing and deadly disease, and remains the leading cause of death.

Cardium Therapeutics, a California-based health sciences and regenerative medicine company, is one of the few companies with a focus on both of these major markets. The company’s primary lead product, Generx, is designed to do what no traditional heart treatment medications can do, actually stimulate the growth of blood vessels around the heart in order to enhance myocardial blood flow in heart disease patients. Other drug therapies are designed simply to reduce pain. Excellagen, Cardium’s lead commercial product, already FDA-cleared, is designed to accelerate the healing process of things like diabetic foot ulcers, a critical problem for diabetes patients. An added benefit is that it can improve healing of many other types of wounds.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

The Vital Diversity of Cardium Therapeutics (CXM)

Monday, June 3rd, 2013

The length of time and associated costs involved in the development of important therapeutic medicines can put a serious strain on funding resources. In the case of Cardium Therapeutics and their one-of-a-kind DNA-based angiogenic growth factor therapeutic, Generx, being developed for the treatment of patients with advanced coronary artery disease, rather than depending upon outside direct funding sources, the company recognized that it was vital to have a long-term reliable income strategy. Cardium has chosen to diversify, providing layers of short-term and long-term support for their ongoing research, while building a broad marketplace presence.

•    Generx – Generx (alferminogene tadenovec, Ad5FGF-4) is uniquely designed to stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. It represents an important contrast to traditional drug therapies, such as nitrates and beta blockers, which only provide transient symptomatic relief of anginal chest pain without addressing the underlying disease. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe.
•    Excellagen – The company’s lead commercial product, Excellagen, is a syringe-based, professional-use, pharmaceutically-formulated gel that functions as an acellular biological modulator, designed to accelerate the growth of granulation tissue and to activate the wound healing process. Excellagen is FDA-cleared for the treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds, and is intended for professional use.
•    To Go Brands – In October, 2012, Cardium acquired the assets, business and product portfolio of To Go Brands. To Go Brands develops, markets, and sells a portfolio of products including nutraceutical powder mixes, supplements and chews to support healthy lifestyles. The product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements.

Cardium is involved in the development of other health related products as well, and plans to continue to review acquisitions of other companies and licenses covering product opportunities and technologies.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Reports Favorable Recommendations from ISS and Glass Lewis For Upcoming Proposals

Tuesday, May 28th, 2013

Today before the opening bell, Cardium Therapeutics announced that Institutional Shareholder Services, Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), the nation’s leading independent proxy advisory firms, each recommend that Cardium’s stockholders vote “FOR” all proposals in the proxy statement and recommends a “1 Year” advisory say on pay frequency with respect to the matters that will be considered at the company’s annual meeting scheduled for June 6, 2013.

“We are pleased that Glass Lewis and ISS, the leading independent proxy and corporate governance advisory firms whose recommendations are relied upon by institutional shareholders, have recommended in favor of all proposals contained in our recent proxy statement. Each of these firms recommend a vote “For” the following: (1) re-election our Class I Directors, Edward W. Gabrielson, M.D. and Lon E. Otremba; (2) approval of the compensation paid to our named executive officers; (3) approval of the sale of the Series A Convertible Preferred Stock; (4) approval of a reverse stock split (5) approval of an increase to authorized common stock; and (6) ratification of the selection of our independent auditors. Our Board of Directors encourages all stockholders to submit their proxies in support of the Company’s proposals,” stated Christopher J. Reinhard, Cardium’s Chairman and CEO.

Cardium’s proxy statement and any other materials filed by the company with the SEC can be obtained at the SEC’s website at www.sec.gov or from www.cardiumthx.com. Only stockholders who held the company’s common stock as of the record date of April 26, 2013 are eligible to vote at the annual meeting. As always, the proxy statement should be read carefully before making any voting decision.

Those who have questions about the upcoming, voting methods, or proxy materials should contact Cardium’s proxy advisor, Georgeson, at 888-219-832.

For more information, visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Trims Q1 2013 Loss, Improves Sales

Wednesday, May 15th, 2013

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments.

The company narrowed its first-quarter loss to $2.2 million from a net loss of $2.6 million for the comparable three months of 2012.

Sales in the first quarter totaled $599,000, an increase compared to sales of $20,000 reported for the same period in 2012. The company attributes the increase in sales to its To Go Brands health science-based operating unit, which represents roughly 92 percent of total product sales, and sales of the Excellagen advanced wound care product, which represents 8 percent of total product sales.

Research and development costs for the quarter were $762,000, as compared to $1.2 million for the prior year period. Cardium attributes the decrease to lower expenses related to the development of Excellagen, partially offset by increased costs associated with the company’s ongoing Generx ASPIRE study.

Cardium also highlighted recent achievements including:

• Awarded ISO 13485 Certification for Excellagen; State of California manufacturing license and state clearances to market and sell Excellagen in the U.S.; and advanced other international registrations for Excellagen, including CE Mark registration, which the company expects to receive approval on or around the end of Q2 2013.
• Signed sales and distribution agreement with Academy Medical, LLC to market, sell and distribute Excellagen to U.S. government medical providers. Excellagen awarded the American Podiatric Medical Association’s Seal of Approval for its contributions to better foot health and mobility.
• Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting highlighting Excellagen’s capability of promoting rapid granulation and complete healing in three difficult and complex post-surgical wounds, including Mohs surgery and wound dehiscence.
• Presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC, “Optimizing Phase III Trial Design for Generx® (Ad5FGF-4).”
• Publication of the paper, “Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors,” in the April issue of Molecular Therapy publication.
• Expanded To Go Brands® VitaRocks® kids vitamin product line and broadened retail distribution of the newly-designed products into select nationwide Target stores.

For more information visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Plays Two Vital Roles in the Fight Against Diabetes

Friday, May 10th, 2013

As hard as it may seem to believe, the American Diabetes Association says that over 8% of the U.S. population, roughly 1 out of 12 Americans, now has diabetes. That’s nearly 26 million people, though perhaps 1/4 of those afflicted have yet to be formally diagnosed with the disease. Even more chilling is the fact that almost 80 million people are estimated to have prediabetes, where blood glucose levels are higher than normal, but not yet at the level of type 2 diabetes. Such people are more likely to eventually develop diabetes.

In the U.S., diabetes costs almost a quarter of a trillion dollars annually, and is the cause, or a contributing factor, in nearly a quarter of a million deaths each year. The lack of exercise, as people spend more time in passive interface with electronics, coupled with high-carb diets, has led to an epidemic of obesity, leading in turn to an epidemic of diabetes.

Diabetes can produce a number of debilitating symptoms, two of which, cardiovascular disease and chronic wounds, are both directly targeted by California-based medical technology company Cardium Therapeutics.

Diabetes greatly increases the risk of heart disease and stroke, and Cardium’s primary development product Generx is an important angiogenic growth factor therapeutic for the treatment of cardiovascular disease. Unlike traditional drugs for treating heart disease, Generx is designed to actually increase blood flow around the heart. It is seen as being of value on a global basis, representing a far less costly or technically complex way of addressing heart disease. Generx can be administered non-surgically, using a standard cardiac infusion catheter, and it can stimulate the natural process of blood vessel growth in the heart’s microcirculation that is not reachable by surgical intervention. As such, it is a welcome alternative to elaborate and expensive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents.

Cardium’s other important product for dealing with the problems of diabetes is Excellagen, an FDA-cleared wound treatment gel that has already been shown to significantly aid healing for many types of wounds, including diabetic foot ulcers. It’s easy to use and a number of physicians have reported observing a rapid onset of the growth of granulation tissue in a wide array of wounds, including classic non-healing diabetic foot ulcers. Cardium already has ISO certification to sell Excellagen in the U.S., and the company is now in the final commercialization stages for the product.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) CSO Dr. Rubanyi Authors Generx Publication in Molecular Therapy

Thursday, May 2nd, 2013

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today highlighted the publication, “Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors,” authored by Gabor M Rubanyi, M.D., Ph.D., Cardium’s chief scientific officer in the April issue of Molecular Therapy.

The publication frameworks the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the optimization of clinical trial designs, including information on designating appropriate clinical trial endpoints, selecting patients who are likely responders to therapeutic stimulation of collateral development, and potential genetic and molecular markers in patient screening.

Dr. Rubanyi also summarizes the knowledge gained in the last 15 years of pre-clinical and clinical research and development initiatives in the field of therapeutic angiogenesis using growth factor proteins and genes.

“I also described in some detail the specific insights that our team, first at Schering AG (now part of Bayer Healthcare) and now at Cardium, has gained in the course of the development of Generx, one of the most advanced therapeutic angiogenesis product candidates,” Dr. Rubanyi stated in the press release. “These lessons have been invaluable and they have been incorporated into the trial design of the Generx ASPIRE pivotal phase 3 clinical study now underway at several leading cardiovascular centers in the Russian Federation.”

Generx is Cardium’s interventional cardiology-focused product candidate currently in development as a non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (CMI).

The abstract of the publication is available at www.nature.com/mt/journal/v21/n4/abs/mt201313a.html (membership required for full viewing). The company will mail the full article to interested parties upon request by contacting Cardium at 858-436-1000.

For more information visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) to Showcase Excellagen® in Poster Presentation at the 2013 Spring SAWC/WHS Meeting

Tuesday, April 30th, 2013

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, is scheduled to present a poster demonstrating the clinical benefits of its lead commercial product, Excellagen®, at The Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting to be held May 1-5, 2013, in Denver, Colorado.

Authored by Steven Smith, M.D., Mohs surgeon, of Wellesley, Mass, the presentation titled “Accelerated Granulation and Healing of Problematic Post-Surgical Wounds with Formulated Collagen Gel 2.6%” will be presented by Lois Chandler, Ph.D., Cardium’s vice president of Biologics Development.

As an advanced regenerative wound product, Excellagen is capable of promoting rapid granulation and complete healing in three difficult and complex post-surgical wounds, including Mohs surgery and wound dehiscence. The presentation highlights these capabilities and presents the case that Excellagen has eliminated the need for expensive secondary reconstruction and/or skilled nursing care.

The 2013 Spring SAWC/WHS meeting gives Cardium the opportunity to exhibit Excellagen’s capabilities to more than 2,000 attendees, including physicians, podiatrists, nurses, therapists, and researchers who specialize in wound management.

The poster presentation can be viewed at www.excellagen.com/meetings-and-publications.html.

For more information visit www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Looks to Future with Three-Stage Growth Plan

Monday, April 29th, 2013

Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they have successfully positioned themselves in several markets, much like a rocket with multiple stages timed for continuous acceleration.

Immediate revenue is provided through Cardium’s To Go Brands subsidiary, acquired in 2012, which markets and sells a growing portfolio of over 25 healthy lifestyle products, including nutraceutical powder mixes and supplements designed for both convenience and health of active lifestyle consumers. Their product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements. It’s a big and fast growing market, projected by some to top $200 billion over the next several years, and should continue to provide Cardium with an important source of revenue to support their other developments.

Further down the timeline, but not too far, is Excellagen, Cardium’s FDA-cleared wound treatment gel that has already been proven to significantly aid healing for many types of wounds, including diabetic foot ulcers. The company is in the final commercialization stages for Excellagen, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations. The ease of use and effectiveness of this new treatment, together with the fact that it has broad application potential, bodes well for future revenue.

And finally there is Generx, an important DNA-based angiogenic growth factor therapeutic, designed to actively increase blood flow around the heart for the treatment of heart disease. The product is qualitatively different than traditional drugs for treating heart disease, drugs which only address the pain or future blockages. It is still under development, but Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Continues with Growth Strategy Implementation

Friday, April 19th, 2013

When Cardium Therapeutics recently released their 2012 financial results, reflecting the company’s extensive investment required for the important introduction of Excellagen and nutraceutical initiatives, and the initiation of their Generx ASPIRE clinical study, the standout feature of the report was the extensive list of achievements put in place to drive Cardium’s long-term growth strategy.

Cardium is actively advancing its Generx DNA-based angiogenic growth factor therapeutic, a one-of-a-kind treatment for heart blood flow problems which, unlike other treatments, actually stimulates blood vessel growth in the heart. Closer to market is the company’s Excellagen wound treatment product, which will eventually help support the Generx program. Cardium’s nutraceutical initiatives, centered around the company’s recent acquisition of To Go Brands, are already providing the significant source of income.

Relating to Generx, the report indicated that Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods. The company made a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum held in Washington, DC, and has also received a favorable patent decision in Europe, along with a successful resolution of a competition over rights to key methods for the application of cardiovascular gene therapy in the treatment of coronary heart disease.

The report also highlighted a number of accomplishments related to Cardium’s continuing progress in the commercialization of its FDA-cleared Excellagen product, a wound treatment gel that has been shown to significantly improve healing for many types of wounds. Cardium has now entered into a logistics and cold chain services agreement with Smith Medical Partners, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations.

Separately, Cardium has now established a strong foothold in the revenue-generating nutraceutical industry, through its successful acquisition of To Go Brands nutraceutical supplement platform, with over 25 products being developed and sold through established regional and national food, drug, and mass channel retailers at over 10,000 retail locations. In addition, the company has developed a new in-house partner-enabled product opportunity, LifeAgain, a set of algorithms and programs to support specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Excellagen Commercialization Plans

Friday, April 12th, 2013

Cardium Therapeutics, a medical technology company focused on cardiovascular and tissue repair, has developed and is implementing a comprehensive commercialization strategy for Excellagen, the company’s novel syringe-based gel to boost the healing process for all types of wounds, including diabetic ulcers, surgical wounds, trauma wounds, and chronic vascular ulcers. The product’s proven effectiveness, range of application, and ease of use has opened an extensive target market, which Cardium is addressing with a variety of partnership agreements.

In January 2013, Cardium announced a distribution agreement with Academy Medical to market, sell, and distribute Excellagen to U.S. government medical providers. Academy Medical has a growing customer base of over 35 VA and military hospitals within the U.S. Cardium also recently announced an agreement with an independent regional distributor group, consisting of ten sales representatives, to market, sell, and distribute Excellagen to podiatric and orthopedic physicians, plastic surgeons, hospitals, and surgical centers. They plan to enter into additional agreements to introduce Excellagen to a variety of regional markets while broadening its potential applications in wound care.

Cardium is also establishing strategic partnerships to cover the marketing and sale of Excellagen into U.S. vertical wound healing market channels, including: (1) podiatry, (2) wound care centers, hospitals, and long-term care facilities, (3) government agency providers (such as the U.S. Department of Veterans Affairs, Bureau of Indian Affairs, and military hospitals), (4) dermatology and plastic surgery, and (5) orthopedic surgery. This is a proven approach similar to other companies in the advanced wound care space.

Cardium is also actively pursuing a reimbursement process for Excellagen with Centers for Medicare & Medicaid Services and private insurance providers. Already-established standard CPT procedure reimbursement codes may apply when Excellagen is used with surgical debridement procedures and through the DRG reimbursement system for in-hospital surgical procedures, as well as in long-term care facilities and through their service providers.

Internationally, Cardium plans to obtain a CE Mark for the potential marketing and sale of Excellagen in the 27-country European Union, and expects to obtain a CE Mark for Excellagen in the second quarter of 2013. The company also has a marketing and distribution agreement with BL&H Co. for the marketing and sale of Excellagen in South Korea, which is currently advancing through the regulatory and reimbursement pricing process. In addition, Advanced Biosciences Research, an affiliate of bioRASI, is assisting Cardium for the planned commercialization of Excellagen in Russia and the eight additional member countries comprising the Commonwealth of Independent States (CIS).

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Reports 2012 Financial Results, Recent Developments, and Financing

Friday, April 5th, 2013

Today before the opening bell, Cardium made a series of announcements as well as provided a comprehensive update on its ongoing initiatives. An abridged overview is presented below due to the length of the press releases issued. For detailed information, visit Cardium’s news page at http://dtg.fm/1thP.

Commercialization of FDA-Cleared Excellagen

• Introduced its FDA-cleared Excellagen® professional-use wound care product in March 2012 and entered into a logistics and cold chain services agreement with Smith Medical Partners, a subsidiary of H. D. Smith;

• Awarded ISO 13485:2003 certification for Excellagen, State of California manufacturing license and state clearances to market and sell Excellagen in the U.S., and advanced other international registrations for Excellagen, including CE Mark registration, which is expected in Q2 2013;

• Announced sales and distribution agreements with Academy Medical to market, sell, and distribute Excellagen to its growing base of over 35 U.S. government medical providers, including Veterans Administration and military hospitals;

• Excellagen selected as one of the Top Ten Podiatry Innovations in 2012 by Podiatry Today publication, and awarded the American Podiatric Medical Association’s Seal of Approval for Excellagen’s contributions to improve foot health and mobility;

• Formed the Excellagen Medical Advisory Board comprising leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care, and presented case studies at the Desert Foot 2012 High Risk Diabetic Foot Conference;

• Entered into international agreements with (1) an established pharmaceutical company for the registration, marketing, and distribution of Excellagen in the South Korean market; and (2) Advanced Biosciences Research for the planned commercialization of Excellagen in the Russian Federation and CIS;

• Advanced forward with applications to support the reimbursement process for Excellagen with the Centers for Medicare & Medicaid Services (CMS) and private insurance providers, and broadened marketing and sales efforts into markets with established CPT® codes for surgical debridement procedures and in-hospital surgical markets covered under DRG reimbursement systems.

Advancing Generx Phase 3 Angiogenic Gene Therapy

• Initiated the ASPIRE Phase 3 registration study, a 100-patient randomized and controlled multi-center study being conducted at leading cardiology centers in Russia;

• Published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods demonstrating that Cardium’s innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after a one-time intracoronary administration of adenovector in mammalian hearts;

• Presented at the 2013 Phacilitate Annual Cell & Gene Therapy Forum held in Washington, DC, “Optimizing Phase III Trial Design for Generx (Ad5FGF-4)” on adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and discussed the lessons learned during the past decade of the company’s Generx clinical development program;

• Favorable patent decision in Europe and successful resolution of a long standing competition between Cardium and its licensor, the University of California, and Boston Scientific Corporation and its licensor, Arch Development, over the rights to key methods for the application of cardiovascular gene therapy in the treatment of coronary heart disease, as is employed in the company’s Generx gene therapy candidate.

Health Sciences Business and Other Strategic Product Initiatives

• Acquired To Go Brands® nutraceutical supplement brand platform with over 25 products being developed and sold through established regional and national food, drug, and mass channel retailers at over 10,000 retail locations;

• Announced expansion of the To Go Brands VitaRocks® Kids vitamin products and retail distribution of the newly-designed VitaRocks product line into select Target stores nationwide;

• Reported plans for the partner-enabled clinical development of Genedexa™ (previously referred to as the Excellarate™ product candidate), a DNA-based Phase 2b/3 product candidate initially for the treatment of chronic, non-healing diabetic foot ulcers and representing the first product extension from the company’s FDA-cleared Excellagen technology platform;

• Developed a new in-house partner-enabled product opportunity, LifeAgain™, a medical analytics and e-commerce platform of algorithms and medical-based programs that were developed by Cardium researchers to support a strategically partnered commercialization of specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases.

Further Announcements

Cardium invested heavily into its current initiatives, spending $2.6 million for research and development and $6.1 million in selling, general, and administrative expenses. The increased expenditure was associated with the market introduction of Excellagen, initiation of the company’s Generx ASPIRE clinical study, and for Cardium’s nutraceutical initiative, which served as the catalyst for the acquisition of To Go Brands.

In other news, Cardium reported a definitive agreement with its largest shareholder for a financing of up to $4.0 million in gross proceeds. The proceeds will be used to further build Cardium’s medical opportunities portfolio, including its FDA-cleared Excellagen product which is being introduced into targeted would care markets, among other things.

Detailed information on Cardium’s commercialization plans for Excellagen and Generx, as well as an overview of the To Go Brands® Nutraceutical Brand Platform and various in-house initiatives, can be found at http://dtg.fm/W5oO.

To learn more about Cardium Therapeutics and its medical portfolio, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Addresses the High Cost of Heart Surgery

Monday, April 1st, 2013

The number and degree of medical advances over the past 50 years is astonishing, offering hope for the afflicted never before possible or even imaginable. But it’s hope that comes with a very steep price. Regardless of who pays the bill, or how efficiently everything is administered, the cost of applying the latest technologies is going to be high, whether in the form of drugs, diagnostic instrumentation, or complex surgeries. As existing technologies mature, costs can decrease, but the use of mature technologies is inevitably replaced by a demand for even newer drugs, instrumentation, and procedures. When a loved one’s life is at stake, everyone wants the best.

In the case of heart disease, the world’s #1 killer, the costs can be staggering. Angioplasty and stent procedures to improve blood flow to the heart can cost tens of thousands of dollars, and coronary bypass surgery can cost hundreds of thousands of dollars. Multiply such costs by the number of patients who receive coronary revascularizations each year (over a million in the U.S. alone), together with the costs associated with all of the complications that can result, and the impact on healthcare costs becomes clear.

Such numbers drive home the importance of Generx, the lead clinical development product candidate of Cardium Therapeutics. Unlike traditional heart treatment drugs that only treat the pain of heart blood flow problems, requiring expensive procedures like the above to deal with actual blood flow, Generx is able to stimulate the growth of blood vessels in the heart. As a cost-effective and easy-to-apply alternative to invasive procedures, the target market for the drug is deep and worldwide. In countries where the access to technology and associated funding is limited, Generx could represent a desperately needed option. The drug has already completed four randomized clinical studies in the U.S. and Europe.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Builds a Diverse Approach to the Medical and Health Marketplace

Wednesday, March 20th, 2013

Cardium Therapeutics is implementing a broad-based strategy of engaging the medical and health marketplace, focused on opportunities offering a clear path to monetization.

Generx, Cardium’s lead clinical development product candidate, is unique in its ability to stimulate the growth of blood vessels in the heart for patients with insufficient blood flow as the result of cardiovascular disease. Instead of invasive and terribly expensive operations such as coronary angioplasty or bypass surgery, or taking traditional anti-anginal drugs that simply treat the pain, Cardium’s Generx product candidate offers a potential non-surgical and less expensive therapeutic option. This is of special importance in many developing countries where technology limitations and cost factors result in reduced treatment options for patients. Generx has already progressed through four randomized clinical studies at over 100 medical centers in the U.S. and Europe and has commenced the ASPIRE Phase 3 registration study at up to nine leading cardiology centers in Russia.

Excellagen, Cardium’s FDA-cleared, professional use treatment for neuropathic diabetic foot ulcers and other dermal wounds, offers an especially easy-to-use treatment that has shown a statistically significant relative improvement in the rate of healing (reduction in wound radius) during the first two weeks following a one-time application compared to patients receiving standard of care therapy. Genedexa is the first planned product extension of the Excellagen platform. Internationally, Cardium plans to obtain a CE Mark for the potential marketing and sale of Excellagen in the European Union, which consists of 27 member countries.

The company’s portfolio extends into the healthy lifestyle arena with the recent purchase of To Go Brands, which develops and sells a portfolio of over 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles. The product line contains 100% natural antioxidant-rich drink mixes with organic ingredients in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, as well as capsule-based dietary supplements.

For more information visit, www.cardiumthx.com

Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Excellagen Wound Care Product Receives ISO Certification

Thursday, March 14th, 2013

Today before the bell, Cardium Therapeutics announced that it has received ISO 13485:2003 certification for its Excellagen® advanced wound care product by BSI, one of the world’s leading certification bodies. This certification is a stand-alone standard developed by the International Organization for Standardization that provides harmonized quality management systems requirements for manufacturers of medical devices. Cardium’s compliance with ISO 13485 represents an important next step forward to compliance with European regulatory requirements.

“This ISO certification represents a major achievement and milestone for Cardium and moves us forward in our CE Mark Certification application for authorization to market and sell Excellagen in the European Union, which currently consists of 27 member countries,” stated Christopher J. Reinhard, Chairman and CEO of Cardium Therapeutics.

Cardium also reported today that it has completed its submission of required documentation including the technical file and design dossier of its CE mark filing for review by BSI. Additionally, Angel Biomedical’s operations has been acquired by a United Kingdom-based private equity company. Angel Biomedical is responsible for a segment of Excellagen’s collagen manufacturing process. It is expected that the new entity, Collbio Ltd., will continue manufacturing of new batches required for their ISO re-certification, which is necessary for final certification of Cardium’s CE mark application, in the second quarter 2013. Cardium previously established a supply of manufactured bulk collagen in the United States and does not anticipate any disruption in the Excellagen supply chain.

For more information on Cardium Therapeutics, visit www.cardiumthx.com

Let us hear your thoughts below: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Prepares Launch of Expanded VitaRocks® kids Vitamin Line with New Retail Distribution

Wednesday, March 13th, 2013

Earlier today, Cardium Therapeutics announced that its To Go Brands® division has expanded its VitaRocks® kids vitamins product line and that retail distribution of the newly-designed products is being been expanded to include select Target stores.

The VitaRocks products are inspired by a popping pellet candy that is popular with kids and represents a next-generation, easy-use delivery platform for multivitamins and nutrients, dietary supplements, and potentially over-the-counter (OTC) medicines for children as well as adults. The Kids VitaRocks product line tastes great and delivers important vitamins and minerals needed by the body. Each packet provides 50% of Daily Value, so that children four and above can safely enjoy this nutritious treat twice a day. VitaRocks products include cherryBLAST, grapeGUSHER, the new blueRAZZ, as well as orangeBURST, providing 250 mg of Vitamin C. To Go Brands’ adult VitaRocks C delivers a powerful dose of 1000 mg of Vitamin C in every packet.

“Special formulations allow VitaRocks to melt cleanly in the mouth and deliver vitamins and nutrients while being fun and great tasting. Unlike many other products in this class, VitaRocks require no mixing with water and can be directly consumed. While the initial product line was designed for children, with the success of new adult multivitamin chews and gummies, consumers of all ages are increasingly seeking easy-to-use and great tasting nutritional products, and we believe that our VitaRocks platform aligns with this important and rapidly emerging trend. Because of our unique manufacturing process, we now have the flexibility to expand the product line into formulas that could include enzymes, electrolytes, amino acids, vitamins and minerals, as well as nutrients, and into other applications including OTC drugs,” stated Hanna Wagari, Cardium’s Vice President of Sales and Marketing.

Current VitaRocks products are available through retailers, including Whole Foods, Sprouts and Vitamin Shoppe. The new product line will be available at the beginning of April 2013 in select Target stores, as well as directly from the To Go Brands web-based store at www.togobrands.com.

For more information on Cardium, visit www.cardiumthx.com

Let us hear your thoughts below: Cardium Therapeutics, Inc. Message Board

Cardium Therapeutics, Inc. (CXM) Generx Cardiovascular Solution Marches to a Different Beat

Thursday, February 28th, 2013

Coronary artery disease – the No. 1 cause of death worldwide – kills more than 17 million people around the world each year. It’s easy to skim over the statistics when “death” dominates global headlines. We are desensitized to a bold and ruthless serial killer among us that has literally stopped millions of hearts dead in their tracks. The real clincher is that this killer can be stopped.

Health and active living advocates have exposed cardiovascular disease for what it really is – an often self-inflicted disease that could be prevented by adhering to a healthy lifestyle. Despite an increasingly educated population, the human race, collectively, isn’t ready to forfeit poor eating choices and wise-up to heart health. That’s why regenerative medicine company Cardium Therapeutics is conducting countless hours of research and development to offer a non-conventional approach to coronary artery disease.

Traditional treatments for heart disease ranges from drug therapy to highly invasive bypass surgeries, stents, angioplasty, and grafts. Cardium’s counter solution is a one-time, non-surgical gene-based treatment option called Generx, administered using a standard cardiac infusion catheter.

Generx is designed to work with and enhance the body’s natural healing process by stimulating blood vessel growth in the heart, which in turn generates blood flow. Clinical studies of Generx show improved cardiac perfusion (blood flow, in this case) within eight weeks. To-date, Generx has completed four randomized clinical studies at more than 100 medical centers in the United States and Western Europe.

Cardium plans to enroll 100 men and women with myocardial ischemia from coronary artery disease for the upcoming ASPIRE phase 3 clinical study to evaluate the Generex’ safety and efficacy. The ASPIRE study will mark the fifth clinical study under Generex’ clinical development program, which will prepare the company to seek regulatory approval from the Russian Health Authority.

For more information, visit www.cardiumthx.com

Let us hear your thoughts below:

Cardium Therapeutics, Inc. (CXM) and the Generx Strategy

Wednesday, February 20th, 2013

Cardium Therapeutics’ lead clinical development product candidate is Generx, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Unlike other coronary drug therapeutics, Generx is designed to actually stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe.

Generx is designed as a disease-modifying regenerative medicine therapeutic that can elicit structural and physiologic changes in the heart (the growth of new collateral blood vessels) following a one-time intracoronary administration from a standard cardiac infusion catheter. In contrast, traditional drug therapies such as nitrates and beta blockers provide transient symptomatic relief of anginal chest pain without changing the underlying disease.

It’s ease of use and cost effectiveness make Generx of special potential value in parts of the world where heart disease is increasing, but system availabilities and cost factors make invasive surgical procedures such as coronary angioplasty and stenting, or cardiac bypass surgery, unrealistic. Places like China, India, Russia, as well as Latin America and the Middle East represent vast target markets for Generx. Even in highly industrialized parts of the world, such as the U.S. and Europe, heart disease remains a major problem, and the cost of surgical procedures is putting a growing strain on already over-burdened healthcare systems.

Cardium’s strategy is to move forward with clinical studies for Generx at major medical centers in Russia in connection with commercialization plans covering the marketing and sale of Generx in the Russian Federation. In addition, Cardium will seek clinical development and commercialization partners for Generx in other newly-industrializing countries, such as India, China, and Brazil.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts below:

Cardium Therapeutics, Inc. (CXM) Wound Care Product Awarded Seal of Approval by American Podiatric Medical Association

Tuesday, February 12th, 2013

Today before the opening bell, Cardium Therapeutics announced that the American Podiatric Medical Association (APMA) has granted its prestigious Seal of Approval to Excellagen®, Cardium’s advanced, FDA-cleared wound care product, for improving foot health and mobility. Excellagen is a syringe-based, professional-use, pharmaceutically formulated 2.6% fibrillar Type I bovine collagen gel that functions to activate the wound healing process and accelerate the growth of granulation tissue. Excellagen can be used to treat neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds.

APMA, the nation’s leading professional organization for podiatrists, has 53 state component locations across the United States and its territories, with a membership of more than 12,000 licensed podiatrists. Excellagen passed an extensive scientific review by a panel of APMA members and was recommended by a committee of Doctors of Podiatric Medicine (DPMs) to the APMA Board of Trustees. For more information, visit www.apma.org.

“Excellagen has proven to be an important treatment for wound care and has been thoroughly reviewed and found to be beneficial to foot health. For this reason, it has been granted APMA’s Seal of Approval,” stated Joseph M. Caporusso, DPM, President of the APMA.

“We are pleased to receive the highly regarded APMA Seal of Approval for our Excellagen advanced wound care product. The APMA assists physicians and their patients to make informed decisions about their foot health, and we are proud that Excellagen has completed the thorough review process and met the APMA’s standards and requirements for its Seal of Approval. Excellagen was also selected as a 2012 Top 10 Innovations in Podiatry by Podiatry Today publication and we appreciate the industry recognition that Excellagen is now receiving,” commented Christopher J. Reinhard, Cardium’s Chairman and CEO.

In other news today, the company also announced that it has retained an additional independent distributor group consisting of ten sales representatives to market, sell, and distribute Excellagen to podiatric and orthopedic physicians, plastic surgeons, hospitals, and surgical centers located in North Carolina and South Carolina. The distributor’s customer base specializes in the treatment of diabetic foot ulcers and surgical wounds, including post-Mohs cancer surgery and trauma wounds. On January 3, 2013, Cardium announced a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals. Academy Medical has a growing customer base of over 35 VA and military hospitals within the U.S.

Reinhard concluded, “The addition of our new regional distributor and our recent agreement with Academy Medical will expand our distribution capabilities for Excellagen as we advance forward with our planned U.S. strategic partnering activities. Consistent with our long-term business strategy, we do not plan to establish an internal sales force for Excellagen and continue to focus on broadening representation, marketing and sales, and co-promotional arrangements targeting four U.S. vertical wound healing market channels: (1) podiatry, (2) wound care centers, hospitals and long-term care facilities, (3) government medical service providers; and (4) dermatology. We are also advancing international registrations for Excellagen, including CE Mark registration, which is expected in first quarter 2013, to enable marketing and sales in the European Union and in other international markets where the CE Mark is considered an important commercial recognition of quality.”

For more information on Cardium and its advanced wound care product, visit www.cardiumthx.com

Let us hear your thoughts below: